Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.66 |
| ▸ | APP | P05067 | 1/20 | 0.65 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811614 | 0.86 | MAOB (0.64) | MAOBAPPCYP3A4F2TP53 | |
| SCHEMBL851722 | 0.85 | MAOB (0.59) | MAOBAPPSMPD1CYP3A4MAOA | |
| SCHEMBL5866132 | 0.85 | TSHR (0.48) | MAOBAPPSMPD1CYP3A4TP53 | |
| SCHEMBL27510264 | 0.84 | MAOB (0.53) | MAOBAPPSMPD1CYP3A4F2 | |
| Hydrochloric Acid SCHEMBL5866134 | 0.84 | TSHR (0.47) | MAOBAPPSMPD1CYP3A4TP53 | |
| SCHEMBL3900543 | 0.83 | MAOB (0.59) | MAOBAPPF2MAOAAS3MT | |
| SCHEMBL18223726 | 0.83 | MAOB (0.61) | MAOBSMPD1CYP3A4SPHK2F2 | |
| SCHEMBL4699319 | 0.83 | SMPD1 (0.64) | MAOBAPPSMPD1CYP3A4SPHK2 | |
| SCHEMBL8618909 | 0.81 | MAOB (0.85) | MAOBAPPSMPD1RAB9A | |
| SCHEMBL18614360 | 0.81 | SMPD1 (0.59) | MAOBSMPD1CYP3A4SPHK2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885APP 3580/4885SMPD1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.